Breast Center, Department of Obstetrics and Gynecology, University Hospital of Cologne, Cologne, Germany.
Curr Opin Obstet Gynecol. 2010 Feb;22(1):79-86. doi: 10.1097/GCO.0b013e328334e462.
An improved understanding of the important role of angiogenesis in tumor biology has led to development of different antiangiogenic therapies. This review highlights therapeutic agents from recent breast cancer trials showing the greatest potential for further clinical use in the near future.
Numerous clinical studies for several antiangiogenic agents have recently been conducted in breast cancer patients and different antiangiogenic approaches have demonstrated their antitumor activity. Bevacizumab is the most advanced agent, being the first approved angiogenesis inhibitor in metastatic breast cancer. The multikinase inhibitors sorafenib, sunitinib, and pazopanib have also shown promising early results and are further evaluated. To maximize efficacy and safety of antiangiogenic agents and help selecting patients suitable for this therapy, identification of predictive biomarkers is essential.
Novel antiangiogenic agents have produced positive data in clinical trials for breast cancer leading to the approval of bevacizumab for the first-line therapy of metastatic breast cancer. Other interesting substances such as multikinase inhibitors are currently being investigated. So far, angiogenesis inhibitors provide an additional therapeutic option for metastatic breast cancer; their role in early breast cancer as well as optimal patient selection will need further research.
对血管生成在肿瘤生物学中重要作用的认识不断提高，导致了不同的抗血管生成治疗方法的发展。本综述重点介绍了最近乳腺癌试验中的治疗药物，这些药物在不久的将来具有进一步临床应用的最大潜力。
最近在乳腺癌患者中进行了多项针对多种抗血管生成药物的临床研究，不同的抗血管生成方法已经证明了其抗肿瘤活性。贝伐珠单抗是最先进的药物，是转移性乳腺癌中第一个被批准的血管生成抑制剂。多激酶抑制剂索拉非尼、舒尼替尼和帕唑帕尼也显示出了有希望的早期结果，并正在进一步评估。为了最大限度地提高抗血管生成药物的疗效和安全性，并帮助选择适合这种治疗的患者，识别预测性生物标志物是至关重要的。
新型抗血管生成药物在乳腺癌临床试验中产生了积极的数据，导致贝伐珠单抗被批准用于转移性乳腺癌的一线治疗。其他有趣的物质，如多激酶抑制剂，目前正在研究中。到目前为止，血管生成抑制剂为转移性乳腺癌提供了另一种治疗选择；它们在早期乳腺癌中的作用以及最佳患者选择仍需要进一步研究。
